cystic fibrosis; F508del cystic fibrosis transmembrane conductance regulator corrector; F508del cystic fibrosis transmembrane conductance regulator rescue; chloride transport CYSTIC FIBROSIS TRANSMEMBRANE conductance regulator (CFTR) is a glycosylated protein that functions as a plasma membrane chloride and bicarbonate channel (2) and modulates salt and water transport across epithelial cell membranes of various tissues (24, 34) . CFTR is comprised of two membrane-spanning domains (MSD1 and MSD2), two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain (R) (49) . CFTR activation requires both ATP binding to the interface between NBD1 and NBD2 and protein kinase A (PKA)-mediated phosphorylation of the R domain (6, 11, 13, 64) . A large number of cellular chaperones and cochaperones participate in regulating the correct folding of CFTR (31) . The deletion of the phenylalanine residue at position 508 (F508del) in the NBD1 domain is the most common class II mutation in cystic fibrosis (CF) and results in a folding defect of F508del CFTR, its retention in the endoplasmic reticulum (ER), and the premature degradation by the ubiquitin-proteasome system (UPS). The small amount of F508del CFTR that escapes from UPS and reaches the plasma membrane functions poorly and is unstable on the plasma membrane with a half-life on the cell surface significantly shorter than that of the wild-type (wt) protein (22, 37, 54) . The consequent F508del CFTR-dependent ionic imbalance and the aberrant fluid homeostasis at epithelial surfaces in the lung result in the secretion of thick mucus, which impairs the mucociliary clearance favoring the bacterial infections, inflammation, and consequent impairment of lung function (7) .
It has been shown that culturing cells at low temperature (27°C) can rescue the trafficking defect of F508del CFTR and its expression at the cell surface, although still with altered gating of the channel and reduced cell surface density and recycling efficiency (12, 15, 27) . In addition to low temperature culture, chemical compounds such as DMSO (5) , glycerol (53) , or organic solutes (73) increase the processing of the core-glycosylated, endoplasmic reticulum-arrested F508del CFTR into the fully glycosylated mature form of CFTR. These findings, together with the evidence that restoration of small amounts of functional CFTR protein (20 -30% of normal levels) (72) can greatly ameliorate the disease severity, have stimulated a great effort to identify membrane-permeable small-molecule compounds that could either rescue the biosynthetic defect of F508del CFTR thus restoring its folding, trafficking, and insertion into the plasma membrane (correctors) and/or enhance its regulated function once rescued to the surface (potentiators). The potentiators, interacting directly with the NBD1 and NBD2 of CFTR (9) , rapidly increase CFTR channel activation by either an ATP-dependent (25) or -independent (17) mechanism, whereas the correctors require several hours to rescue the functional expression of CFTR.
Most of the presently identified potential correctors have been selected by high-throughput screening, which allows a rapid screening of thousands of small molecules before being validated in "in vitro" culture systems (65, 66) . Some of them have displayed some efficacy in restoring F508del CFTR plasma membrane localization and improving chloride transport (10, 29, 43, 52, 67). In particular, VX-809 (60), developed by Vertex Pharmaceuticals, has resulted to be efficacious in improving F508del CFTR surface expression and chloride transport in cultured human bronchial epithelial cells isolated from CF patients homozygous for the F508del mutation and is presently considered suitable for advancement into Phase III clinical studies in combination with the potentiator VX-770 "Kalydeco" (59) . This combined administration of a potentiator and a corrector together is required to rescue a sufficient functional expression of F508del CFTR at the cell surface, since the F508del mutation displays both trafficking and gating defects.
The mechanism of action of many correctors remains relatively poorly known, and studies to better understand the structure of the CFTR protein and the conformational destabilization of F508del NBD1 are useful to develop new compounds that can bind directly to the mutant protein. In this respect, the identification of a number of folding correctors of F508del CFTR has been discovered in in silico structure-based screening utilizing homology models of CFTR (29) .
Correctors may rescue the functional expression of F508del CFTR either acting as pharmacological chaperones that interact directly with the misfolded F508del CFTR protein favoring its folding and trafficking to the cell surface (36, 52, 68, 70) or as proteostasis regulators modulating the activity of a plethora of pathways involved in F508del CFTR folding and degradation (3, 21, 39) . However, because F508del CFTR trafficking is inhibited by various quality control systems, it is becoming evident that a combination of two different correctors or a corrector and a potentiator together might be necessary to achieve a significant increase in F508del CFTR functional expression and restore the CF symptoms. In this respect, compounds having both corrector and potentiator functions would alleviate this need for multiple combined administrations, but, until now, very few compounds have been identified with both corrector and potentiator activities (32, 44, 46) .
We recently demonstrated that the psoralen-related compound, 4,6,4=-trimethylangelicin (TMA), potentiates the cAMP/PKA-dependent activation of wt CFTR in airway cells (58) . Importantly, here we report that long-term incubation with TMA significantly rescues F508del CFTR functional expression to the cell surface of primary and secondary airway CF cell monolayers, suggesting that, as observed for a few other molecules, TMA may act both as potentiator and corrector. Moreover, previous findings (58) demonstrating that TMA significantly inhibits the expression of the IL-8 gene in airway cells in which the inflammatory response has been challenged with Pseudomonas aeruginosa suggest that TMA may represent a promising lead compound for a potential development of a single drug therapy useful for overcoming the CF defect.
MATERIALS AND METHODS
Cell culture. Experiments were performed in two human immortalized CF bronchial epithelial cell lines: the CFBE41o Ϫ cells, stably overexpressing F508del CFTR, (CFBE⌬F) homozygous for the F508del allele (F508del/F508del) (a generous gift from Dr. J. P. Clancy, University of Cincinnati, Children's Hospital Medical Center, Cincinnati, OH) (4), and the CuFi-1 cells (F508del/F508del CFTR mutant genotype) (a generous gift of Dr. J. Zabner, University of Iowa); the 16HBE14o Ϫ (HBE) expressing endogenous wt CFTR and the CFBE wtCFTR cells (CFBE41o Ϫ , with stable expression of wild-type CFTR) were a generous gift from Dr. D. Gruenert (University of California, San Francisco, CA). HBE, CFBE⌬F, and CFBE wtCFTR cells were grown in complete media (E-MEM, 10% FBS, L-glutamine, and penicillin/streptomycin) at 37°C under 5% CO2. The stably transfected cells were maintained in the presence of 2 g/ml Puromicin (for CFBE⌬F) or 200 g/ml Hygromycin B (for CFBE wtCFTR) positive selection. Cells were routinely grown on flasks coated with an extracellular matrix containing fibronectin/vitrogen/ BSA. CuFi-1 cells were grown on human placental collagen type VI (Sigma)-coated flasks in BEGM medium (Cambrex Bio Science), as previously described (71) .
Fischer rat thyroid (FRT) epithelial cells, stably coexpressing human F508del CFTR and the high-sensitivity halide-sensing green fluorescent analog yellow fluorescent protein (HS-YFP) YFP-H148Q/ I152L (FRT-F508del) or stably transfected with a plasmid coding for P574H-CFTR and carrying the resistance gene for zeocin (FRT-P574H) were a generous gift from Dr. L. J. Galietta (Gaslini Institute, Genoa, Italy). FRT-F508del and FRT-P574H cells were grown in Coon's modified Ham's F-12 medium plus 10% FBS, L-glutamine, and penicillin/streptomycin at 37°C under 5% CO 2. Human Embryonic Kidney 293 (HEK293) cells were grown in DMEM (with 5% FBS, penicillin/streptomycin). HEK293 cells, grown on 35-mm-diameter culture dishes, were transfected with 1 g of plasmid DNA coding for 3HA-wt "human ether-à-go-go-related gene" (hERG) or for 3HA-hERG R752W (a generous gift from Dr. E. Ficker, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH) using Lipofectamine 2000 (Invitrogen).
Human airway epithelial cells, differentiated in a polarized epithelium primary culture (MucilAir), are derived from CF (homozygous for the F508del mutation) and non-CF bronchial biopsies and were provided by Epithelix Sàrl (Geneva, Switzerland). "Italian Cystic Fibrosis Foundation Primary Culture Core Facility" provided other primary cultures of human bronchial epithelial cells derived either from F508del CFTR homozygous donors, CF-BE, and from non-CF donors. All primary cells were maintained at an air-liquid interface (ALI) according to the manufacturer's instructions.
For iodide influx experiments, 20,000 FRT-F508del cells were seeded on each round glass cover slip. For chloride efflux experiments, confocal immunofluorescence analysis, and biotinylation experiments, cells were seeded on 0.4-m-pore size polyethylene terephthalate filter inserts (Falcon BD). For transepithelial current measurements, cells were seeded on 0.4-m-pore size Snapwell polyester membrane inserts (Costar, Corning, NY). The functional experiments were performed when the cell monolayers reached a transepithelial electrical resistance Ͼ1,000 ohm ϫ cm 2 (primary cells) and Ͼ500 ohm ϫ cm 2 (immortalized cells) measured with the Millicell-Electrical Resistance System (Millipore).
The drug TMA was dissolved in 3% DMSO in methanol (vehicle) at a concentration of 2.5 mM (stock solution), whereas VX-809 and VX-770 were dissolved in DMSO at concentrations of 20 and 50 mM, respectively.
The vitality of cells was evaluated after 24 h treatment with vehicle alone or TMA at all tested concentrations by trypan blue exclusion assay and resulted to be Ͼ98%. (pH 7.4) , and subsequently 100 M amiloride was added. The CaCl 2 concentration was increased to 2.4 mM to compensate calcium chelation by the gluconate. The CFTRdependent chloride secretion was stimulated by the concomitant addition of 10 M forskolin (FSK) plus 500 M IBMX to both bathing solutions and, subsequently, by the addition of the potentiator genistein (50 M) . At the end of the experiment, CFTR Inh-172 (10 M) was added to the apical bath solution to inhibit F508del CFTRmediated Isc.
Fluorescence measurements of apical chloride efflux. Chloride efflux was measured using the Cl Ϫ -sensitive dye N-(ethoxy-carbonylmethyl)-6-methoxyquinolinium bromide, MQAE (Sigma). Confluent cell monolayers were loaded overnight in culture medium containing 5 mM MQAE at 37°C in a CO2 incubator and then inserted in a perfusion chamber that allowed independent perfusion of apical and basolateral cell surfaces. Fluorescence was recorded with a Cary Eclipse spectrofluorometer (Varian). To measure chloride efflux rate across the apical membrane, the apical perfusion medium was changed with a medium in which chloride was substituted with iso-osmotic nitrate. All experiments were performed in HEPESbuffered bicarbonate-free media, Cl Ϫ medium (in mM: 135 NaCl, 3 KCl, 1.8 CaCl 2, 0.8 MgSO4, 20 HEPES, 1 KH2PO4, and 11 glucose), and Cl Ϫ -free medium [in mM: 135 NaNO3, 3 KNO3, 0.8 MgSO4, 1 KH 2PO4, 20 HEPES, 5 Ca(NO3)2, and 11 glucose]. At the end of each experiment, a two-point calibration procedure was performed: the maximal intensity of fluorescence (F0) was determined by perfusing the cells with the Cl Ϫ -free medium on both sides of the monolayer; the minimal fluorescence was obtained by then exposing the cells to a solution containing KSCN (in mM: 110 KSCN, 1 MgSO4, 10 HEPES, 1 CaSO 4, 5 glucose, and 0.005 valinomycin). For data analysis, the value for minimal fluorescence was subtracted from the experimentally measured fluorescence, and the resulting fluorescence was divided by the value of F0. The rate of Cl Ϫ efflux was determined by linear regression analysis of 30 points taken at 4-s intervals and expressed in arbitrary slope changes in (F/F0)/min. We measured the apical CFTR-dependent chloride secretion as the difference in the rate of change of FSK plus IBMX-stimulated fluorescence in the absence or presence of apical treatment with CFTR Inh-172 [⌬(F/F0)/min] as described previously (20) .
RNA extraction and quantitative RT-PCR. Total RNA extracted from CFBE⌬F cells treated for 24 h with 100 nM TMA or its vehicle was purified using a High Pure RNA Isolation Kit (Roche, Mannheim, Germany), and 2.0 mg RNA were reverse transcribed to cDNA using the High Capacity cDNA Archive Kit and random primers (Applied Biosystems, Foster City, CA) in a final reaction volume of 20 l. cDNA (5 l) was mixed with TaqMan Fast Advanced Master Mix (Applied Biosystems) and TaqMan gene expression assay (Applied Biosystems) for CFTR (Hs00357011_m1, NM_000492.3) and GAPDH (Hs02758991_g1, NM_002046.4) as normalizer gene. Real-time PCR was performed in duplicate for both target and normalizer genes using the ABI Prism 7900 HT Fast real-time PCR system (Applied Biosystems) as follows: 50°C for 2 min, 95°C for 20 s, and 40 two-step cycles of 95°C for 1 s and 60°C for 20 s. Results were collected with SDS 2.3 software (Applied Biosystems), and relative quantification was performed using the Ct method. Data were analyzed with RQ Manager software 1.2 (Applied Biosystems). Changes in mRNA expression levels were calculated after normalization to calibrator gene.
CFTR immunoblot analysis. Immunoblot analysis was performed as described by Van Goor et al. (60) . Briefly, cells were incubated for 24 h at 37°C with vehicle or TMA or VX-809 or for 24 h at 27°C in culture media. After incubation, cells were harvested in ice-cold D-PBS solution (without calcium and magnesium) and pelleted at 1,000 g at 4°C. Cell pellets were lysed in 1% Nonidet P-40, 0.5% sodium deoxycholate, 200 mM NaCl, 10 mM Tris, pH 7.8, and 1 mM EDTA plus protease inhibitor cocktail (Sigma) for 30 min on ice. Lysates were spun for 10 min at 10,000 g at 4°C to pellet insoluble material. Approximately 30 g total proteins were heated in Laemmli buffer with 5% ␤-mercaptoethanol at 37°C for 5 min and loaded on 3-8% Tris-acetate gel (Bio-Rad). The gel was transferred to polyvinylidene difluoride (PVDF) membranes (GE Healthcare) and processed for Western blotting by using monoclonal CFTR antibody (dilution 1:500; clone: 24-1, MAB25031 R&D Systems) or monoclonal ␤-tubulin antibody (dilution 1:1,000; Sigma). Blots were developed by enhanced chemiluminescence (GE Healthcare). F508del CFTR expression was not significantly altered by the 24-h treatment with the vehicles of TMA or VX-809. Densitometric quantification and image processing were carried out using Photoshop (Adobe Systems) and the NIH Image software package version 1.61 (National Institutes of Health).
Internalization assay and cell surface stability. CFTR internalization was performed as described (28) using a two-step biotinylation protocol. Polarized cell monolayers were cultured at 27°C for 48 h to facilitate F508del CFTR rescue and delivery to the cell surface (62) . In the last 3 h of this incubation, one-third of the monolayers was treated with 100 nM TMA, one-third was treated with the vehicle, and the last third was left untreated. Next, surface carbohydrate groups on the cell surface were oxidized with sodium periodate (NaIO4, 10 mM), washed with ice-cold PBS containing 0.1 mM CaCl 2 and 1 mM MgCl 2 (PBS-CM), and then warmed to 37°C for 2.5 min. Oxidized surface carbohydrate groups remaining on the cell surface after a warm-up period were labeled with biotin-LC-hydrazide (1 mg/ml; Pierce) in PBS-CM for 30 min with gentle agitation. Excess biotin was removed by washing cells two times at 4°C with 0.1 M glycine in PBS-CM. Cells were lysed in biotinylation lysis buffer (BLB: 0.4% sodium deoxycholate, 1% NP-40, 50 mM EGTA, 10 mM Tris-Cl, pH 7.4, and protease inhibitor cocktail). Lysates were centrifuged (10,000 g) to remove cell debris, and total protein levels were determined. Equivalent amounts of cell lysate proteins (400 g) were incubated overnight with 150 l of streptavidin (Pierce). Precipitated proteins were washed three times with BLB, solubilized with Laemmli sample buffer, separated on a 4 -12% SDS-PAGE (Bio-Rad), and blotted for CFTR.
To analyze the TMA effect on rF508del CFTR cell surface stability, cell monolayers were cultured at 27°C for 48 h and incubated in the last 3 h with 100 nM TMA, or its vehicle was then transferred at 37°C and incubated for 0 up to 8 h in the presence of the corrector. Next, cell surface glycoproteins were biotinylated and lysed in BLB buffer and processed as described above.
hERG immunoblot analysis. HEK293 cells, grown on 35-mmdiameter culture dishes, were transiently transfected with 1 g of plasmid DNA coding for 3HA-wt hERG or for 3HA-hERG R752W using Lipofectamine 2000 and were subjected to treatment with correctors 24 h after transfection. After incubation, cells were homogenized in lysis buffer (110 mM NaCl, 50 mM Tris, 0.5% Triton X-100, and 0.5% Igepal CA-630, pH 8, with an added protease inhibitor mixture), sonicated for 10 s, and centrifuged for 10 min (16,000 g), and then the pellet was discarded. Supernatant protein concentration was measured, and an aliquot of 30 g of proteins was diluted in Laemmli buffer, heated at 100°C for 5 min, and separated by Tris/HCl SDS/PAGE (7% gel). The gel was transferred to PVDF membranes (GE Healthcare) and processed for Western blotting by using monoclonal HA antibody (dilution 1:1,000; HA.11 clone: 16B12; Covance) or monoclonal ␤-tubulin antibody (dilution 1:1,000; Sigma).
Immunofluorescence and confocal analysis. Cell monolayers were treated with TMA or VX-809 24 h before analysis. Cells were fixed in 3.7% paraformaldehyde and stained with an anti-CFTR (CF3) mouse monoclonal antibody (dilution 1:500; Abcam) as previously described by us (18) . Goat anti-mouse IgG conjugated to Alexa Fluor 568 (dilution 1:1,000; Invitrogen) was used as secondary antibody. Monolayers were then mounted on slides with Prolong Gold antifade reagent with DAPI (Invitrogen) and examined with a Leica TCS SP5 II microscope equipped with a laser-scanning confocal unit containing an He-Ne argon laser (Leica). Specimens were viewed through a Planapo ϫ63/1.25 oil immersion objective, and images were acquired by the LAS-AF version 2.2.1 software.
Data analysis. Data are presented as means Ϯ SE for the number of samples indicated. Statistical comparisons were made using paired or unpaired data Student's t-test. Differences were considered significant when P Ͻ 0.05.
RESULTS
We have previously demonstrated that the psoralen-related compound, TMA, at nanomolar concentrations inhibits the expression of the IL-8 gene in bronchial epithelial cells in which the inflammatory response has been challenged with P. aeruginosa (58) . In the same study, we observed that acute addition (15 min treatment) of 250 nM TMA potentiated FSK-stimulated chloride secretion in airway cell monolayers expressing wt CFTR or in CF cells in which F508del CFTR has already been rescued to the apical membrane by overexpressing the interacting protein NHERF1 (58) .
The main goal of the present study was to test if TMA, in addition to being a CFTR "potentiator," may also function as a "corrector" of F508del CFTR mistrafficking.
Characterization of TMA as a F508del CFTR corrector in FRT-F508del cells. FRT epithelial cells, coexpressing F508del CFTR and a fluorescent YFP halide sensor (FRT-F508del), were used as an initial screen to test and evaluate long-term TMA effects by measuring iodide influx (43) . TMA (200 nM) or its vehicle was added to each well for 48 h at 37°C, and F508del CFTR-facilitated iodide influx was then determined from the kinetics of decreasing YFP fluorescence following addition of extracellular iodide in the presence of the adenylate cyclase activator FSK (20 M), the phosphodiesterase inhibitor IBMX (100 M), and the well-known CFTR potentiator genistein (50 M) (26) . Examples of representative traces showing TMA-induced iodide influx are shown in Fig. 1A , where it can be seen that TMA produced a large YFP fluorescence decrease corresponding to a significant increase of iodide influx with respect to cells treated only with the vehicle. The specificity of TMA effect on F508del CFTR-dependent iodide influx was verified by inhibition of the TMA-stimulated increase of iodide influx by the specific CFTR inhibitor CFTR Inh -172 (10 M) (Fig. 1, A and C) . Similar results were obtained in FRT-F508del cells treated for 48 h with the established corrector VX-809 (10 M) (60) (Fig. 1, B and C) . TMA (200 nM) started increasing iodide influx in FRT-F508del after 12 h of preincubation, with a maximal effect at 48 h of treatment (data not shown).
We then tested the dose-response effect (50 -500 nM) of 48 h preincubation with TMA and, as shown in Fig. 1D , 50 nM TMA treatment already significantly produced a maximum level of increase of F508del CFTR-facilitated iodide influx. At concentrations Ͼ200 nM, the TMA-induced response decreased even if still greater than control values.
Functional correction of F508del CFTR by TMA in immortalized airway CF cell monolayers. To verify the possibility that TMA may act as a corrector in CF cell monolayers, we then examined the effect of a 24-h preincubation with TMA on F508del CFTR-mediated chloride transport in polarized human airway cells homozygous for the F508del mutation, CFBE⌬F, grown on permeable supports. These cells have been extensively used in the study of other correctors (50, 51, 56, 62) .
After 24 h preincubation with TMA or the vehicle, the rate of chloride efflux was measured by following the change in fluorescence [(F/F 0 )/min] of the chloride-sensitive dye MQAE after replacement of chloride by nitrate in the apical perfusion medium as previously described (20) (Fig. 2, A and B) . The apical F508del CFTR-dependent chloride secretion was calculated as the difference in alterations of 10 M FSK plus 100 M IBMX-stimulated fluorescence in the absence or presence of apical treatment with 5 M CFTR Inh -172 (Fig. 2, C and D) . Dose-response (50 -500 nM TMA) functional experiments were performed to determine the minimum TMA concentration that rescues F508del CFTR-dependent chloride efflux. As shown in Fig. 2E , 50 nM TMA preincubation already significantly restored the F508del CFTR-dependent chloride efflux, and 100 nM TMA produced a maximum level of the rescue of F508del CFTR activity that was 29.3 Ϯ 4.36% of CFTRdependent chloride transport measured in polarized monolayers of 16HBE14o Ϫ (HBE) cells expressing wt CFTR. Moreover, experiments performed after a 48-h preincubation of 100 nM TMA gave similar results to those obtained after 24 h of TMA treatment [0.0169 Ϯ 0.002 ⌬(F/F 0 )/min, n ϭ 11 for 24 h and 0.0160 Ϯ 0.004 ⌬(F/F 0 )/min, n ϭ 4 for 48 h; not significant (NS)].
As found in FRT-F508del cells, at higher TMA concentrations, the response was reduced, resulting in a bell-shaped dose-response relationship as also previously reported for VX-809 (60) and other correctors (50) . The efficacy of TMA as a corrector was analyzed by comparing the effects of TMA preincubation with those obtained by preincubation for 24 h with VX-809 under the identical experimental conditions. We found that 100 nM TMA induced an increase of F508del CFTR-dependent chloride efflux similar to that produced by 5 M VX-809 [0.0179 Ϯ 0.003, ⌬(F/F 0 )/min, n ϭ 6; NS], suggesting a potential advantage of TMA in terms of reduced therapeutic dosage.
To explore the persistence of functional correction promoted by TMA, F508del CFTR-dependent chloride efflux measurements were performed in CFBE⌬F cell monolayers at different times after wash-out of the compound. CFBE⌬F cells were treated with 100 nM TMA for 24 h and then washed with fresh medium and assayed for 10 M FSK plus 100 M IBMXstimulated chloride efflux at different time points up to 24 h. As shown in Fig. 2F, 3 h after wash-out, F508del CFTRdependent chloride efflux was reduced by about 20% of the maximum and remained relatively constant at this level for the remainder of the 24-h period.
Moreover, to verify the effect of TMA preincubation in another immortalized airway CF cell line, we analyzed the CFTR-dependent chloride secretion in CuFi-1 cells, extensively used by various laboratories to study F508del CFTR activity, therapeutic interventions for cystic fibrosis, and innate immunity (14, 58) . We found that 24 h preincubation with 100 nM TMA significantly rescued F508del CFTR-dependent chloride efflux also in polarized CuFi-1 cell monolayers [0.009 Ϯ 0.001, n ϭ 4 vs. 0.002 Ϯ 0.001, n ϭ 3 ⌬(F/F 0 )/min after 24 h preincubation with TMA or vehicle, respectively, P Ͻ 0.01] to a similar level of that induced by 5 M VX-809 (0.010 Ϯ 0.0002, n ϭ 3).
In a parallel series of functional experiments, polarized CFBE⌬F cell monolayers incubated for 24 h in the presence of 100 nM TMA or its vehicle alone were mounted in Ussing chambers for measurements of chloride efflux by I sc analysis. Amiloride (100 M) was added to the apical bath solution to inhibit electrogenic Na ϩ absorption. As shown in Fig. 3A , in CFBE⌬F monolayers treated with TMA, the addition of 10 M FSK plus 500 M IBMX elicited an increase in the I sc that was further increased by the potentiator genistein (50 M). The subsequent addition of the selective CFTR inhibitor CFTR Inh -172 (10 M) caused a drastic decrease of the I sc , . C: summary of these data from 5 independent experiments where the fluorescence decay rate corresponding to iodide influx stimulated by correctors in the absence of (gray bar) and presence of (black bar) CFTRInh-172 is represented. D: dose-response data of the fluorescence decay rate corresponding to F508del CFTR facilitated iodide influx to increasing concentrations from 50 to 500 nM of TMA. Each bar represents the mean Ϯ SE. Statistical comparisons were made using an unpaired Student's t-test (*P Ͻ 0.05, **P Ͻ 0.01, and ****P Ͻ 0.0001). Each bar represents the mean Ϯ SE. F: persistence of TMA-rescued F508del CFTR activity after TMA removal in CFBE⌬F cell monolayers. After 24 h of 100 nM TMA incubation, CFBE⌬F cells were fed with fresh medium without TMA, and CFTR activity was followed for a further 24 h, and F508del CFTR activity was expressed as a percentage of rescued F508del CFTR activity. Statistical comparisons were made with respect to the values obtained in monolayers incubated for 24 h with TMA designed as 100%. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, and ****P Ͻ 0.0001. Figure 3B summarizes the CFTR inh -172-inhibited shortcircuit current (⌬I sc ) measurements obtained in CFBE⌬F cell monolayers preincubated with TMA or its vehicle, demonstrating that 100 nM TMA produces a significant rescue of F508del CFTR-dependent chloride secretion that was equivalent to 26.54 Ϯ 2.30% of that recorded in HBE cell monolayers.
Effect of treatment combinations in rescuing F508del CFTRdependent chloride secretion in CFBE⌬F polarized monolayers.
We then analyzed if the addition of the two correctors TMA and VX-809 together had greater effect compared with the single treatments. F508del CFTR-dependent chloride efflux measurements were performed in CFBE⌬F cell monolayers, by spectrofluorometry, after treatment with 100 nM TMA plus 5 M VX-809 for 24 h. As shown in Fig. 4A , the combined effect of two correctors was not significantly different from the effect induced by each single treatment, suggesting that TMA and VX-809 share a similar mechanism of action to perform their corrector function. On the contrary, TMA correction activity has an additive effect with low temperature (27°C) preincubation (Fig. 4B) .
Evaluation of acute potentiator activity of TMA after its prolonged corrector effect. Next, to determine if the long-term TMA corrector effect on F508del CFTR-dependent chloride efflux can be further increased with the acute addition of a CFTR potentiator, CFBE⌬F monolayers were preincubated for 24 h with 100 nM TMA and then treated for 15 min with either the well-known CFTR potentiator VX-770 (10 M) (59) or with TMA (250 nM) that we previously described to be a potentiator of the wt CFTR or F508del CFTR that has been rescued to the cell membrane by the interacting protein NHERF1 (58) . Indeed, as shown in Fig. 4C , the acute addition of either VX-770 or TMA significantly potentiated the FSK-induced F508del CFTR-dependent chloride secretion, whereas the addition of only the vehicle for either VX-770 or TMA did not significantly alter the effect of TMA preincubation for 24 h [0.01 Ϯ 0.0007, n ϭ 8 vs. 0.008 Ϯ 0.001, n ϭ 3 and 0.008 Ϯ 0.001, n ϭ 3 ⌬(F/F 0 )/min, for TMA-preincubated control and for vehicles for VX-770 and TMA, respectively]. Interestingly, we found that, as reported for other potentiators (46) , the potentiator effect of TMA or VX-770 was unmasked only when the activation of F508del CFTR-dependent chloride efflux in CFBE⌬F cell monolayers was performed with a lower concentration of FSK (1 M) and in the absence of IBMX.
Indeed, the potentiator effect of either VX-770 or TMA was not significantly evident in response to 10 M forskolin stimulation (data not shown).
Effect of TMA treatment on F508del CFTR transcription, expression, and localization in CFBE⌬F cells. To determine if TMA affects CFTR transcription, we used quantitative realtime RT-PCR to assess the effect of TMA treatment on F508del CFTR transcript levels in polarized CFBE⌬F cells, and we observed (Fig. 5A ) that the relative expression of CFTR mRNA was not altered by 100 nM TMA treatment for 24 h, suggesting that this compound may act at the posttranscriptional level.
The biosynthetic processing of F508del CFTR induced by TMA was, therefore, assayed by immunoblot analysis of the accumulation of mature, complex-glycosylated F508del CFTR in CFBE⌬F cells. Figure 5B , left, shows a typical Western blot performed in both CFBE cells stably overexpressing wt CFTR (CFBE wtCFTR) and in CFBE⌬F cells that were preincubated for 24 h with vehicle alone or either 100 nM TMA or 5 M VX-809. In CFBE wtCFTR cells, the mature band C of CFTR was strongly expressed. On the contrary, in the CFBE⌬F cells treated with only vehicle, F508del CFTR was almost completely expressed as the immature band B, and preincubation with either TMA or VX-809 resulted in both the appearance of the mature band C and in an increase of immature band B expression of F508del CFTR protein. Densitometry analysis (Fig. 5B, right) revealed that 24 h pretreatment with TMA or VX-809 increased the mature band C of the F508del CFTR by about 70% with respect to their vehicles, which were normalized to one. It is noteworthy that also the band B was increased to the same extent when cells were exposed to TMA or VX-809 for 24 h. The increase in the core-glycosylated band B could be the result of inhibition of the ubiquitin-proteasome pathway, which has been demonstrated to regulate CFTR degradation (69), or to its stabilization and/or retention in the ER (61) . Further studies are required to clarify these hypotheses.
Because F508del CFTR cannot mature conformationally at 37°C but can avoid ER quality control and proceed to the plasma membrane at 27°C (15), we next compared the TMA effect on F508del CFTR rescue with that induced by 24 h low-temperature treatment (Fig. 5C ). In control conditions at 37°C, F508del CFTR is mostly revealed as band B (ϳ160 kDa), representing the form of the protein residing in the ER. Low-temperature treatment significantly increased the relative abundance of band C and B to the same extent as that produced by TMA incubation.
The finding that TMA incubation increased F508del CFTR expression and, in particular, the mature band C, does not necessarily mean that more F508del CFTR is present in the apical region of the plasma membrane, since band C only indicates the passage of F508del CFTR through the Golgi. Therefore, to determine whether TMA treatment causes F508del CFTR to be redistributed to the apical membrane, we performed immunofluorescence studies by confocal microscopy analysis in nonpermeabilized polarized CFBE⌬F monolayers immunolabeled with a monoclonal primary antibody, CF3, that recognizes a sequence in the first extracellular loop of the human CFTR protein as previously performed by us (18) . As shown in Fig. 5D , TMA preincubation rescued F508del CFTR in the apical membrane of CFBE⌬F cells as specifically detected by CF3 antibody. A similar effect was obtained in the same cell monolayers incubated with 5 M VX-809 for 24 h. Altogether, these data suggest that TMA is able to induce F508del CFTR trafficking from the ER compartment to the apical membrane where it functions as a cAMP-responsive channel with a significant increase in chloride secretion.
We then investigated if TMA preincubation may affect the F508del CFTR endocytosis rate from the cell surface of polarized CFBE⌬F cell monolayers. As it is known, low temperature-rescued F508del CFTR (rF508del CFTR) is unstable on the cell surface and, at 37°C, is rapidly internalized and degraded (12, 54, 55) . We measured the TMA effect on rF508del CFTR endocytosis rates following the two-step biotinylation protocol previously described (28) . CFBE⌬F cell monolayers, cultured for 48 h at 27°C and incubated in the last 3 h with 100 nM TMA or its vehicle, were warmed up at 37°C for 2.5 min to allow the proteins to be internalized. The internalization time of 2.5 min was chosen since in various cell lines it has been found that periodate-oxidized CFTR did not recycle back to the cell surface (62) . Figure 5E shows that TMA (100 nM) significantly slowed down the internalization of rF508del CFTR. Next, we monitored the effect of TMA on the cell surface stability of rF508del CFTR by following the surface pool of rF508del CFTR using the surface biotinylation assay as previously described (27) (Fig. 5F ). We observed that TMA stabilized the glycosylated band C of rF508del CFTR up to 8 h at 37°C with respect to cell CFBE⌬F monolayers not treated (data not shown) or treated with the only vehicle of Western blot of the effect of TMA preincubation or low-temperature treatment on F508del CFTR expression levels in CFBE⌬F cells. Right, the histogram summarizes the relative change in the expression of band B or band C in cells incubated at low temperature or with TMA corrector with respect to F508del CFTR protein band B or band C expression in untreated cells incubated at 37°C set at 1. Mean Ϯ SE of 6 independent experiments (*P Ͻ 0.05 and **P Ͻ 0.01). D: representative confocal immunofluorescence analysis of polarized CFBE⌬F monolayers treated or not with TMA (100 nM) or VX-809 (5 M) for 24 h. Unpermeabilized cells were immunolabeled with a primary mouse monoclonal antibody (CF3) raised against the first extracellular loop of CFTR. Nuclei were stained with DAPI. Confocal scans are shown in the vertical cross section (xz) plane (ap, apical membrane; bl, basolateral region. Scale bar: 10 m). E: effect of TMA treatment on the internalization rate of rF508del CFTR. A representative blot of cell-surface biotinylated F508del CFTR at 0 and 2.5 min of internalization (warm-up time) is shown (top). rF508del CFTR remaining on the cell surface is reported in the histogram as the percentage change in band C density after a 2.5-min internalization step compared with 0 min (n ϭ 4) (bottom) (****P Ͻ 0.0001). F: effect of TMA on rF508del CFTR cell surface stability. Polarized CFBE⌬F cells, cultured at 27°C for 48 h and treated with TMA in the last 3 h, were then transferred to 37°C up to 8 h in the presence of the corrector (red) or its vehicle (black). Cell surface CFTR levels were measured after cell surface biotinylation, and a representative blot is shown (top). Quantification of cell surface CFTR is plotted as the percentage change in density of band C CFTR at different time points (bottom; n ϭ 4).
TMA, suggesting that TMA may partially protect the thermally destabilized F508del CFTR by the peripheral degradation pathways.
Correction of functional expression of F508del CFTR in primary cultures of CF human airway epithelial cells. It has been observed that the efficacy of correctors may be dependent on the cell type used (45) . The reason for the different efficacy of the correctors may be due to the various mechanisms controlling CFTR maturation, trafficking, or degradation that could vary from one cell type to another. In this respect, increasing evidence indicates that primary airway epithelial cells provide the closest "in vitro" representation of the airway epithelium by providing a microenvironment or architecture closer to in vivo situations (35) . Because primary cells derived from different patients can behave differently depending on the genetics and age of individuals from whom the tissue was derived, multiple donors need to be investigated to take into account donor to donor variability. We therefore performed fluorimetric measurements of TMA action on polarized monolayers of primary human bronchial epithelial cells (CF-BE) derived from four different F508del CFTR homozygous individuals (3 CF donors supplied by Italian Cystic Fibrosis Foundation Primary Culture Core Facility and 1 CF donor from Epithelix Sàrl). To simulate the "in vivo" lung conditions, the CF-BE polarized cells were grown on permeable supports at the ALI. As shown in Fig. 6A, 24 h incubation with 100 nM TMA resulted in a significant increase in F508del CFTRdependent chloride secretion in all examined CF-BE monolayers. The increase in F508del CFTR-dependent chloride secretion was 39.60 Ϯ 1.69% of that measured in non-CF cell monolayers derived from four non-CF donor lungs (3 non-CF donors supplied by Italian Cystic Fibrosis Foundation Primary Culture Core Facility and 1 non-CF donor from Epithelix Sàrl).
In a parallel series of functional experiments in Ussing chambers, CFTR-dependent chloride efflux was measured by I sc analysis in primary CF-BE and non-CF cell monolayers derived from two independent donors in each case. In CF-BE cell monolayers, the F508del CFTR-dependent chloride efflux (estimated from the amplitude of CFTR inh -172-inhibited I sc ) in response to 10 . Moreover, to analyze whether the rescue of chloride efflux induced by TMA treatment was accompanied by translocation of F508del CFTR to the apical membrane, as seen above for immortalized CFBE⌬F cells, we performed immunofluorescence studies followed by confocal analysis in the same primary CF-BE monolayers in which we had measured the chloride effluxes. Cell monolayers were immunolabeled with a monoclonal primary antibody for the first extracellular loop of CFTR protein (18) . As shown in Fig. 6B , preincubation with 100 nM TMA for 24 h significantly rescued the localization of F508del CFTR to the apical membrane.
Specific effect of TMA on F508del CFTR correction. Last, to analyze if the correction effect of TMA was specific for the F508del mutation of CFTR, TMA corrector activity was tested on FRT cells stably expressing P574H-CFTR (FRT-P574H), a mutant of CFTR that, like F508del CFTR, is retained at the ER and can be rescued by incubation for 24 h at reduced temperature (42) . FRT-P574H cell monolayers were incubated for 24 h with 100 nM TMA or at 27°C, and the chloride efflux in response to FSK plus IBMX was measured as described in MATERIALS AND METHODS. We found that, indeed, TMA did not We next analyzed the specificity of TMA correction effect by testing the effect of 24 h preincubation with 100 nM TMA on the trafficking to the cell surface of the hERG K ϩ protein channel. Under physiological conditions, wt hERG exhibits two bands of Western blot analysis: the core glycosylated immature form present in ER, represented by a 135-kDa band, and the fully glycosylated mature protein observable as a 155-kDa band, representing the protein trafficked in the Golgi apparatus or at the cell surface. The trafficking mutant R752W hERG is retained in the ER and is rescued to the cell surface by temperature reduction (19) . We found that TMA did not improve the trafficking process of this mutant form of hERG (Fig. 7) , suggesting that, indeed, TMA correction effect was selective for F508del CFTR.
DISCUSSION
Recently, an intensive effort has been made toward the identification of correctors that may act to rescue the processing defect in F508del CFTR (1). Up to now, the best level of correction has been obtained with VX-809, which is selective for F508del CFTR and enhances chloride secretion to ϳ15% of that of non-CF human bronchial cells (60) . The difficulty in achieving higher levels of correction is due to the fact that the F508del mutation induces multiple conformational defects in the mutant protein. Biophysical and biochemical studies have, in fact, shown that the F508del mutation, besides causing a defect in the conformation stability of NBD1 (33), also influences the interdomain assembly of NBD1 with NBD2 (16) as well as the interaction between NBD1 with MSD2 (36). Therefore, to reach the efficacious level of F508del CFTR correction required to achieve substantial clinical benefit in CF, it is becoming evident that it is necessary to make a combined administration of two correctors that display synergistic action (23) or a corrector with a potentiator that counteracts distinct conformational defects in trafficking and activation of F508del CFTR (41, 65) . The inherent difficulties in this combined compound strategy for CF have led to studies to identify dual-acting molecules that may both correct F508del CFTR and potentiate the F508del CFTR-dependent chloride permeability to avoid the need for multiple combined administration. However, as yet, very few dual-acting compounds have been identified (44, 46) .
We have previously found that the acute addition of TMA, at the nanomolar concentrations, potentiates the cAMP/PKAdependent activation of CFTR in airway cells expressing wt CFTR as well as in CF airway cells in which the F508del CFTR has been rescued to the plasma membrane by overexpressing the interacting protein NHERF1 (58) . In the present study, we demonstrated that TMA significantly rescued chloride secretion in FRT cells expressing F508del CFTR as well as in polarized cell monolayers of secondary airway cells such as the CuFi-1 or the CFBE⌬F overexpressing F508del CFTR. Furthermore, in CFBE⌬F cells preincubated with TMA, we found that the F508del CFTR-dependent chloride efflux in response to a submaximal FSK concentration was further increased by acute addition of the CFTR potentiator, VX-770 (59), or by the acute addition of TMA itself (Fig. 4C ). This finding is in agreement with a previously reported study demonstrating that TMA is a potentiator of CFTR function (58) .
The TMA-dependent functional rescue of F508del CFTR in CFBE⌬F was accompanied by a significant increase of the amount of fully glycosylated mature band C that represents the aliquot of F508del CFTR that acquires a more stable conformation that is not recognized as defective by the ER quality control (16) and may traffic to the Golgi and be delivered to the plasma membrane. Confocal immunolocalization analysis performed in polarized CFBE⌬F cell monolayers confirmed that F508del CFTR rescued by TMA is significantly expressed on the apical membrane region. Moreover, when we compared, under identical experimental conditions, the TMA preincubation effects on the functional expression of F508del CFTR with those observed in the presence of the established corrector VX-809 (60), we found that TMA displays a similar corrector effectiveness at lower concentrations.
The findings that corrector activity is strongly influenced by the cell background indicate that the corrector effect needs to be tested in different cell systems, including primary cultures of bronchial epithelial cells (45) . We found that the TMA effect is not influenced by the cell background since its corrector activity was also detected in primary human bronchial epithelial cells isolated from lungs of patients homozygous for F508del mutation. In primary CF-BE cell monolayers, derived from different CF donors homozygous for the F508del mutation, we reported that 100 nM TMA produced a significant increase in 1) chloride secretion in response to cAMP/PKA stimulation and 2) F508del CFTR expression on the apical membrane of polarized monolayers. Importantly, we found that the extent of F508del CFTR-dependent chloride efflux rescued by TMA preincubation in primary CF-BE cell monolayers reached ϳ35-39% of the CFTR-dependent chloride secretion measured in primary non-CF cell monolayers under the same cAMP/PKA-dependent CFTR activation conditions.
The correctors discovered to date may be functionally characterized either as pharmacological chaperones that interact directly with the misfolded F508del CFTR protein favoring its folding or as proteostasis regulators that act by modulating the pathways involved in F508del CFTR biogenesis and/or degradation. That the TMA corrector effect was not influenced by the cell background, together with the results demonstrating both the persistence of the TMA corrector effect on the F508del CFTR-dependent chloride secretion (Fig. 2F ) and the TMA effect in enhancing the cell surface stability of F508del CFTR (Fig. 5, E and F) , suggest that TMA, by interacting with and improving F508del CFTR folding, protects it from the peripheral degradation pathways (40) . Moreover, we found that, when the CFBE⌬F cells were treated with TMA in combination with VX-809, which displays some characteristics of a pharmacological chaperone (60) , no additional effect was observed, whereas, on the contrary, TMA displayed an additive effect with low temperature preincubation, which has been considered to be a proteostasis regulator since it causes a profound alteration in the cell transcriptome (56) .
Whereas the dual corrector-potentiator activity of TMA could be consistent with a direct binding of TMA with F508del CFTR, on the basis of our results, we cannot establish the molecular mechanism by which TMA exerts the corrector and potentiator activities since these TMA effects could involve distinct TMA-binding sites on F508del CFTR protein or different targets involved in cellular protein homeostasis, and further studies are needed to clarify this point.
Importantly, we found that TMA corrector activity is specific for the F508del mutation since TMA incubation fails to activate the temperature-sensitive mutant P574H-CFTR (42) . Moreover, the findings demonstrating that TMA does not improve the processing of mutant form R752W of hERG, a protein that uses a similar trafficking pathway as CFTR (19) , are consistent with the hypothesis that TMA selectively improves the F508del CFTR processing even if further studies are required to evaluate other possible off-target specificities.
Our previous findings demonstrated that preincubation of TMA is able to decrease the expression of the IL-8 gene in airway cells in which the inflammatory response has been challenged with P. aeruginosa (58) , at the same concentration range and time length (24 h ) that rescues F508del CFTR. Defective CFTR protein has been found associated with a sterile lung inflammation in early cystic fibrosis infants (30) . This has been related to the intracellular signals induced by mutated CFTR and/or because of altered electrolyte transport (8, 47) , although the relationship between CFTR protein defect and the pathogenesis of inflammation in early CF lung disease is still under scrutiny (48) . Interestingly, it has been reported that correction of chloride transport itself, mediated by CFTR or TMEM16A, suppresses the secretion of IL-8 and proinflammatory cytokines in bronchial airway cells in vitro (63) . Although it is conceivable that TMA can reduce the release of IL-8 also because of its correction of the ion transport defect, which can result in downmodulation of the different steps of the proinflammatory signaling, including the activity of NF-kB, this issue still requires further investigation.
In conclusion, our results suggest that TMA, besides having an anti-inflammatory action, acts as a F508del CFTR corrector and potentiator at nanomolar concentrations. A deeper understanding of its mechanism of action will be important in the development of more active analogs. 
